Cancer development and its response to therapy are regulated by inflammation, which
either promotes or suppresses tumor progression, potentially displaying opposing effects on …

The emergence of immunotherapy has been an astounding breakthrough in cancer
treatments. In particular, immune checkpoint inhibitors, targeting PD-1 and CTLA-4, have …

Under steady-state conditions, bone marrow-derived immature myeloid cells (IMC)
differentiate into granulocytes, macrophages and dendritic cells (DCs). This differentiation is …

We describe results from IMmotion150, a randomized phase 2 study of atezolizumab (anti-
PD-L1) alone or combined with bevacizumab (anti-VEGF) versus sunitinib in 305 patients …

Lung cancer is the leading cause of cancer-related death across the world. Unlike lung
adenocarcinoma, patients with lung squamous cell carcinoma (LSCC) have not benefitted …

Cancer immunotherapy (CIT) with antibodies targeting the programmed cell death 1 protein
(PD-1)/programmed cell death 1 ligand 1 (PD-L1) axis have changed the standard of care in …

Both immune checkpoint inhibitors (ICI) and antiangiogenesis agents have changed the
landscape of cancer treatment in the modern era. While antiangiogenesis agents have …

Immunotherapies have revolutionized medical oncology following the remarkable and, in
some cases, unprecedented outcomes observed in certain groups of patients with cancer …

It is now well established that cancer cells co-exist within a complex environment with
stromal cells and depend for their growth and dissemination on tight and plastic interactions …

Myeloid-derived suppressor cells (MDSC) are a diverse population of immature myeloid
cells that have potent immune-suppressive activity. Studies in both mice and humans have …